Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima
Madan, Ravi Amrit
Theoret, Marc Robert
Arlen, Philip M.
Strauss, Julius
Chun, Guinevere
Couvillon, Anna
Harold, Nancy
Chen, Clara
Dawson, Nancy Ann
Apolo, Andrea Borghese
Steinberg, Seth M.
Trepel, Jane B.
Wright, John Joseph
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NCI, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA
[5] NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD USA
[6] Lombardi Comprehens Canc Ctr, Washington, DC USA
[7] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[8] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[9] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[10] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzal, Fatima
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Phillp M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).
    Karzai, Fatima H.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Wright, John Joseph
    Trepel, Jane B.
    Beatson, Melony A.
    Harold, Nancy
    Couvillon, Anna
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [9] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Groshen, Susan G.
    Quinn, David I.
    Goldkorn, Amir
    Martel, Cynthia L.
    Pinski, Jacek K.
    Kuhn, Pater
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345